» Articles » PMID: 34181566

Oxytocin Levels in Response to Pituitary Provocation Tests in Healthy Volunteers

Abstract

Objective: Oxytocin, secreted into circulation through the posterior pituitary, regulates lactation, weight, and socio-behavioral functioning. Oxytocin deficiency has been suggested in patients with hypopituitarism; however, diagnostic testing for oxytocin deficiency has not been developed. The aim of this study was to investigate known pituitary provocation tests to stimulate plasma oxytocin.

Design: Sixty-five healthy volunteers underwent either the hypertonic saline or arginine infusion test, known to stimulate copeptin, or the oral macimorelin test, known to stimulate growth hormone. Plasma oxytocin was measured before and once plasma sodium level ≥ 150 mmol/L for the hypertonic saline, after 60 min for the arginine infusion, and after 45 min for the oral macimorelin test (expected peak of copeptin and growth hormone levels, respectively). Primary outcome was a change from basal to stimulated oxytocin levels using paired t-tests.

Results: As expected, copeptin increased in response to hypertonic saline and arginine infusion (P < 0.001), and growth hormone increased to oral macimorelin (P < 0.001). Oxytocin increased in response to hypertonic saline infusion from 0.4 (0.2) to 0.6 pg/mL (0.3) (P = 0.003) but with a high variance. There was no change to arginine infusion (P = 0.4), and a trend to lower stimulated levels to oral macimorelin (P = 0.05).

Conclusion: Neither the arginine infusion nor the oral macimorelin test stimulates plasma oxytocin levels, whereas there was an increase with high variance upon hypertonic saline infusion. As a predictable rise in most participants is required for a reliable pituitary provocation test, none of the investigated pituitary provocation tests can be recommended diagnostically to identify patients with an oxytocin deficiency.

Citing Articles

Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans.

Galbiati F, Galbiati F, Plessow F, Plessow F, Plummer L, Plummer L Eur J Endocrinol. 2025; 192(3):K24-K29.

PMID: 39965102 PMC: 11886556. DOI: 10.1093/ejendo/lvaf001.


Oxytocin levels in response to CRH administration in hypopituitarism and hypothalamic damage: a randomized, crossover, placebo-controlled trial.

Asla Q, Garrido M, Urgell E, Terzan S, Santos A, Fernandez M Sci Rep. 2025; 15(1):2360.

PMID: 39824923 PMC: 11742408. DOI: 10.1038/s41598-025-86566-y.


An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management.

Iglesias P J Clin Med. 2024; 13(20).

PMID: 39458112 PMC: 11508259. DOI: 10.3390/jcm13206161.


Understanding oxytocin in human physiology and pathophysiology: A path towards therapeutics.

Lawson E Compr Psychoneuroendocrinol. 2024; 19:100242.

PMID: 38974962 PMC: 11225698. DOI: 10.1016/j.cpnec.2024.100242.


Plasma oxytocin levels in response to glucagon in patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls.

Atila C, Mekkattu S, Murugesu R, Gaisl O, Varghese N, Eckert A Endocrine. 2024; 86(2):774-781.

PMID: 38935296 PMC: 11489228. DOI: 10.1007/s12020-024-03920-2.


References
1.
Blackburn R, Samson W, Fulton R, Stricker E, Verbalis J . Central oxytocin inhibition of salt appetite in rats: evidence for differential sensing of plasma sodium and osmolality. Proc Natl Acad Sci U S A. 1993; 90(21):10380-4. PMC: 47778. DOI: 10.1073/pnas.90.21.10380. View

2.
Molitch M, Clemmons D, Malozowski S, Merriam G, Vance M . Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(6):1587-609. DOI: 10.1210/jc.2011-0179. View

3.
Holze F, Vizeli P, Muller F, Ley L, Duerig R, Varghese N . Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 2019; 45(3):462-471. PMC: 6969135. DOI: 10.1038/s41386-019-0569-3. View

4.
Scantamburlo G, Hansenne M, Fuchs S, Pitchot W, Marechal P, Pequeux C . Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology. 2007; 32(4):407-10. DOI: 10.1016/j.psyneuen.2007.01.009. View

5.
Parker K, Oztan O, Libove R, Sumiyoshi R, Jackson L, Karhson D . Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Natl Acad Sci U S A. 2017; 114(30):8119-8124. PMC: 5544319. DOI: 10.1073/pnas.1705521114. View